← Eichor
Condition: Locally Advanced Biliary Tract Cancers Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Biliary Tract Cancers

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
Phase 3 · 3 location(s) · Rajiv Gandhi Cancer Institute & Research Center, India · NCT06712420A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/Phase 2 · 43 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06431490AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06778031Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2 · 41 location(s) · UNICANCER · NCT06529718XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07670273Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Phase 2 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07450976Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 19 location(s) · Yuhan Corporation · NCT05523947A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2 · 1 location(s) · Beth Israel Deaconess Medical Center · NCT05655949Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Phase 1/Phase 2 · 1 location(s) · Tongji Hospital · NCT07392541Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT05705492A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metas
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07606599The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07582315Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Phase 3 · 270 location(s) · AstraZeneca · NCT06467357A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expressio
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07704177
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.